Showing 451-460 of 9073 results for "".
Antioxidants and Sunscreens
https://practicaldermatology.com/topics/skin-cancer-photoprotection/antioxidants-and-sunscreens--esapeged/19091/Jennifer Linder, MD, FAAD explains the science behind antioxidants in sunscreens and discusses the benefits of using antioxidants along with SPF.Sunscreen Water Seems All Washed Up; Fake Cosmeceuticals Raise Concerns
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-sunscreen-water-seems-all-washed-up-fake-cosmeceuticals-raise-concerns/19119/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine we take a look at drinkable sunscreen and school bans on sunscreens, get an update on Vegas Cosmetic Surgery, and meet the new face of AMBI skincare. Plus, our DermFocus investigates the problem of counterfeit cosHoya ConBio - Laser Assisted Hair Reduction
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/hoya-conbio-laser-assisted-hair-reduction/19461/Video demonstrations on the different settings to use for laser assisted hair reduction.New Clinical Guidelines for Nonmelanoma Skin Cancer Treatment; Arctics Biotherapeutics Seeks New FDA Approval for ZORYVE Foam
https://practicaldermatology.com/series/dermwire-tv/new-clinical-guidelines-for-nonmelanoma-skin-cancer-treatment-arctics-biotherapeutics-seeks-new-fda-approval-for-zoryve-foam/26745/In this week’s DermwireTV, new clinical guidelines for nonmelanoma skin cancer treatment; Arcutis Biotherapeutics seeks new FDA approval for ZORYVE foam; Practical Dermatology joins the ReachMD network; and the CEO of SofWave Medical joins us to discuss the company’s Ultrasound technology.Part 3, 1726 nm lasers: How to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is to be patient
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24341/Chapter 3 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is toPart 4, 1726 nm lasers: Handling referred patients who are already on different treatment regimens
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24342/Chapter 4 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about handling referred patients who are already on different treatment regimens.Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
https://practicaldermatology.com/series/dermwire-tv/study-examines-association-between-childhood-bmi-and-risk-of-developing-imsds/27004/In this week's DermwireTV, a new study examines the relationship between childhood BMI and skin diseases; phase 3 data sheds new light on dupilumab’s effect on inflammatory biomarkers in pediatric AD patients; and the president and CEO of Evolus discusses trends in the injectables market.FDA Approval for Delgocitinib
https://practicaldermatology.com/series/c-suite-chats/fda-approval-for-delgocitinib/36650/Robert Spurr, EVP, North America for LEO Pharma, discusses the importance of an FDA-approved option for treating moderate-to-severe chronic hand eczema in adults.New Treatment Option for Androgenetic Alopecia
https://practicaldermatology.com/series/c-suite-chats/new-treatment-option-for-androgenetic-alopecia/32969/Reid Waldman, MD, Co-Founder and CEO of Veradermics, discusses the prevalence of androgenetic alopecia-pattern hair loss and the company's investigational treatment candidate.The Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succe